Thyrocare Q1 FY27 results: revenue up 26%, PAT up 39% YoY

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.8%Reaction day

₹544.95

prior close

₹560.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.4%+3.4% vs market

Healthcare Service Provider peers, median of 23sector-0.1%+3.9% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.4

10m

+3.1

15m

+1.3

30m

+4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.8+0.4+3.4-0.1+3.9

Next day

+7.0+1.8+5.2+0.3+6.7

+6.1+0.5+5.6+0.2+5.8

+6.1+0.9+5.2+0.7+5.4

+8.3+0.3+7.9-0.8+9.0

+6.1+1.4+4.6-0.2+6.2

+10.9+3.2+7.7+1.8+9.1

15d

+14.7+5.4+9.3-1.8+16.4

+7.5+6.4+1.2-0.9+8.4

+4.3+6.3-2.0-0.3+4.6

-12.8-3.6-9.2-9.4-3.5

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Thyrocare Tech Q1 FY27: Standalone revenue Rs 225.66 Cr, up 26% YoY. PAT rose 39% YoY to Rs 50.17 Cr. Consolidated revenue Rs 240.02 Cr (up 24%), PAT Rs 51.33 Cr (up 34%). EPS Rs 3.15. Board re-appointed Ernst & Young as Internal Auditor for FY27. Auditors gave unmodified conclusion.

Likely market impact

Strong Q1 with double-digit revenue and profit growth; positive momentum for shareholders.